Abstract:Since the first case of human avian influenza A (H7N9) virus infection in 2013, five H7N9 epidemics have occurred in China, all of which caused severe diseases, including pneumonia and acute respiratory distress syndrome, and the fatality rates of these epidemics were as high as 30-40%. To control the prevalence of H7N9 influenza, an effective vaccine is urgently needed. In the present study, we used chitosan and recombinant human interleukin-2 as an adjuvant (JY) to promote the systemic and mucosal immune responses induced by the H7N9 vaccine. Mice were immunized intranasally with the inactivated split influenza A (H7N9) virus (A/Shanghai/02/2013) vaccine with or without JY. The hemagglutination inhibition (HI) titers of mice immunized with the JY-adjuvanted vaccine were significantly higher than those of mice immunized with the vaccine without adjuvant (21.11 +/- 9.58 vs. 5.04 +/- 3, P < 0.05). The JY-adjuvanted H7N9 nasal spray vaccine induced higher HI titers (8 +/- 0.82 vs. 6.7 +/- 0.67, P = 0.0035) than those did the poly (I:C)-adjuvanted H7N9 vaccine or the LTB-adjuvanted H7N9 vaccine (8 +/- 0.82 vs. 6.9 +/- 0.88, P = 0 .01 86). The optimal immunization regimen for the nasal spray H7N9 vaccine was determined to be a 21-day interval between the primary immunization and booster, with a dose of 4.5 mu g hemagglutinin per mouse. The immunogenicities of the nasal spray H7N9 vaccine and intramuscular vaccine (containing only the inactivated split virus) were compared in mice. Two doses of the nasal spray H7N9 vaccine induced higher titers of HI (6.7 +/- 0.67 vs. 5.3 +/- 1.16, P = 0.004) and anti-HA IgG in sera (19.26 +/- 0.67 vs. 13.97 +/- 0.82, P < 0.0001) and of anti-HA sIgA (7.13 +/- 2.54 vs. 0, P = 0 .0000) in bronchoalveolar lavage fluid (BALF) than one dose of intramuscular H7N9 vaccine 3 weeks after the last immunization. However, when we immunized the mice with two doses of both vaccines separately, the nasal spray H7N9 vaccine induced higher titers of anti-HA IgG (19.26 +/- 0.67 vs. 17.56 +/- 0.57, P < 0.0001) and anti-HA sIgA (7.13 +/- 2.54 vs. 4.02 +/- 0.33, P = 0.0026) than did the intramuscular H7N9 vaccine, and there was no difference in HI titer between the two groups (P = 0.3745). This finding indicates that the JY-adjuvanted nasal spray H7N9 vaccine induced not only the systemic immune response but also a local mucosal response, which may improve the efficacy of H7N9 influenza prevention through respiratory tract transmission.

Immunologic effects of mannatide as a new adjuvant of H1N1 split vaccine

Intranasal Immunization Using Mannatide As a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59

Immune cell receptor-specific nanoparticles as a potent adjuvant for nasal split influenza vaccine delivery

The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response

Differential Immune Response Patterns Induced by Anionic and Cationic Lipid Adjuvants in Intranasal Anti-Influenza Immunization

A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung

Polysaccharide from Atractylodes macrocephala Koidz Binding with Zinc Oxide Nanoparticles as a Novel Mucosal Immune Adjuvant for H9N2 Inactivated Vaccine

Intranasal Immunization With Recombinant Ha And Mast Cell Activator C48/80 Elicits Protective Immunity Against 2009 Pandemic H1n1 Influenza In Mice

Conjugating Influenza a (H1N1) Antigen to N‐trimethylaminoethylmethacrylate Chitosan Nanoparticles Improves the Immunogenicity of the Antigen after Nasal Administration

Adjuvant synergy: The effects of nasal coadministration of adjuvants

An Adjuvanted Vaccine-Induced Pathogenesis Following Influenza Virus Infection

Analysis of the immunogenicity and bioactivities of a split influenza A/H7N9 vaccine mixed with MF59 adjuvant in BALB/c mice

Preliminary Study on Type I Interferon As a Mucosal Adjuvant for Human Respiratory Syncytial Virus F Protein

Mucosal immunity of mannose-modified chitosan microspheres loaded with the nontyepable Haemophilus influenzae outer membrane protein P6 in BALB/c mice.

A Glycolipid α-GalCer Derivative, 7DW8-5 as a Novel Mucosal Adjuvant for the Split Inactivated Influenza Vaccine

Systemic and Mucosal Humoral Immune Responses Induced by the JY-adjuvanted Nasal Spray H7N9 Vaccine in Mice.

Intranasal Vaccination Of Recombinant H5n1 Ha1 Proteins Fused With Foldon And Fc Induces Strong Mucosal Immune Responses With Neutralizing Activity: Implication For Developing Novel Mucosal Influenza Vaccines

NK cell membrane/MnO 2 hybrid nanoparticle-adjuvanted intranasal vaccines synergistically boost protective immunity against H1N1 influenza infection

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines

Enhancing Immune Response and Heterosubtypic Protection Ability of Inactivated H7N9 Vaccine by Using STING Agonist as a Mucosal Adjuvant.